Overview

* Atara Q3 2025 revenue beats analyst expectations despite a significant year-over-year decline

* Company reported a net loss of $4.3 mln for Q3 2025, down from $21.9 mln in 2024

* Atara reduced workforce by 29% to focus on strategic priorities

Outlook

* Atara expects $40 mln milestone payment upon tab-cel BLA approval

* Company projects 2025 operating expenses to decrease by at least 60%

* Atara explores strategic alternatives to maximize shareholder value

Result Drivers

* TAB-CEL TRANSFER - Completion of tab-cel activities transfer to Pierre Fabre Laboratories, including BLA sponsorship and costs, expected to reduce operating expenses

* WORKFORCE REDUCTION - Atara reduced workforce by 29% to focus on strategic priorities, retaining essential employees

* CASH FLOW IMPACT - Decrease in cash receipts from Pierre Fabre after 2024 milestones contributed to increased net cash used in operating activities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $3.45 $1.40

Revenue mln mln (3

Analysts

)

Q3 EPS -$0.32

Q3 Net -$4.30

Income mln

Q3 -$3.57

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for Atara Biotherapeutics Inc ( ATRA ) is $16.50, about 23.9% above its November 11 closing price of $12.56

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)